ASCO 2019: SOLO3 Reveals Superiority of Olaparib Over Non-Platinum Chemotherapy in Relapsed Ovarian Cancer
Improvements in objective response were clinically significant
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.